JP2003514771A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003514771A5 JP2003514771A5 JP2001522994A JP2001522994A JP2003514771A5 JP 2003514771 A5 JP2003514771 A5 JP 2003514771A5 JP 2001522994 A JP2001522994 A JP 2001522994A JP 2001522994 A JP2001522994 A JP 2001522994A JP 2003514771 A5 JP2003514771 A5 JP 2003514771A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- a3rag
- active ingredient
- adenosine
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 45
- 239000004480 active ingredient Substances 0.000 description 37
- 229940122216 Adenosine A3 receptor agonist Drugs 0.000 description 12
- 239000002593 adenosine A3 receptor agonist Substances 0.000 description 12
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 231100000331 toxic Toxicity 0.000 description 9
- 230000002588 toxic effect Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940122614 Adenosine receptor agonist Drugs 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- -1 C1~ C10Haloalkyl Chemical group 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 201000002364 leukopenia Diseases 0.000 description 4
- 231100001022 leukopenia Toxicity 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 229940124049 Adenosine A2 receptor antagonist Drugs 0.000 description 3
- 239000003449 adenosine A2 receptor antagonist Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 3
- 125000001475 halogen functional group Chemical group 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 101150007969 ADORA1 gene Proteins 0.000 description 2
- 229940119226 Adenosine A2 receptor agonist Drugs 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000002597 adenosine A2 receptor agonist Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- XTPOZVLRZZIEBW-SCFUHWHPSA-N (2r,3r,4s,5r)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical group C1=CC(N)=CC=C1CCNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XTPOZVLRZZIEBW-SCFUHWHPSA-N 0.000 description 1
- IPSYPUKKXMNCNQ-PFHKOEEOSA-N (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IPSYPUKKXMNCNQ-PFHKOEEOSA-N 0.000 description 1
- LDYMCRRFCMRFKB-MOROJQBDSA-N (2s,3s,4r,5r)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=CC(N)=CC=3)=C2N=C1 LDYMCRRFCMRFKB-MOROJQBDSA-N 0.000 description 1
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 description 1
- 108010041368 Adenosine A2 Receptors Proteins 0.000 description 1
- 102000000506 Adenosine A2 Receptors Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical group OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910003813 NRa Inorganic materials 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003931 anilides Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002648 azanetriyl group Chemical group *N(*)* 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 230000007085 granulocyte colony-stimulating factor production Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 150000003833 nucleoside derivatives Chemical group 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005030 pyridylthio group Chemical group N1=C(C=CC=C1)S* 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL131864 | 1999-09-10 | ||
| IL13186499A IL131864A0 (en) | 1999-09-10 | 1999-09-10 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| IL133680 | 1999-12-23 | ||
| IL13368099A IL133680A0 (en) | 1999-09-10 | 1999-12-23 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| PCT/IL2000/000550 WO2001019360A2 (en) | 1999-09-10 | 2000-09-08 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007128137A Division JP2007204496A (ja) | 1999-09-10 | 2007-05-14 | アデノシン受容体アゴニストまたはアンタゴニストを含む製薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003514771A JP2003514771A (ja) | 2003-04-22 |
| JP2003514771A5 true JP2003514771A5 (https=) | 2006-02-16 |
| JP4980530B2 JP4980530B2 (ja) | 2012-07-18 |
Family
ID=26323880
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001522994A Expired - Lifetime JP4980530B2 (ja) | 1999-09-10 | 2000-09-08 | アデノシン受容体アゴニストまたはアンタゴニストを含む製薬組成物 |
| JP2007128137A Pending JP2007204496A (ja) | 1999-09-10 | 2007-05-14 | アデノシン受容体アゴニストまたはアンタゴニストを含む製薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007128137A Pending JP2007204496A (ja) | 1999-09-10 | 2007-05-14 | アデノシン受容体アゴニストまたはアンタゴニストを含む製薬組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7064112B1 (https=) |
| EP (1) | EP1261322B1 (https=) |
| JP (2) | JP4980530B2 (https=) |
| KR (2) | KR100584797B1 (https=) |
| CN (1) | CN100358512C (https=) |
| AU (1) | AU782826B2 (https=) |
| BR (1) | BR0013905A (https=) |
| CA (1) | CA2384111C (https=) |
| DE (1) | DE60037277T2 (https=) |
| DK (1) | DK1261322T3 (https=) |
| ES (1) | ES2296637T3 (https=) |
| HK (1) | HK1052653B (https=) |
| HU (1) | HU226913B1 (https=) |
| IL (1) | IL133680A0 (https=) |
| MX (1) | MXPA02002546A (https=) |
| PL (1) | PL199852B1 (https=) |
| PT (1) | PT1261322E (https=) |
| RU (1) | RU2239455C2 (https=) |
| WO (1) | WO2001019360A2 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL121272A (en) * | 1997-07-10 | 2000-06-01 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia |
| AU2001281817B2 (en) * | 2000-06-21 | 2005-11-24 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
| US7589075B2 (en) | 2001-01-16 | 2009-09-15 | Can-Fite Biopharma Ltd. | Use of an adenosine A3 receptor agonist for inhibition of viral replication |
| US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
| US20040204481A1 (en) * | 2001-04-12 | 2004-10-14 | Pnina Fishman | Activation of natural killer cells by adenosine A3 receptor agonists |
| US7049303B2 (en) * | 2001-11-07 | 2006-05-23 | Medical Research Council | Inhibition of viruses |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| JP2006503574A (ja) * | 2002-10-22 | 2006-02-02 | カン−フィテ・バイオファーマ・リミテッド | 疾患の状態に関するマーカーとしてのａ３ａｒ |
| US7087761B2 (en) | 2003-01-07 | 2006-08-08 | Hoffmann-La Roche Inc. | Cyclization process for substituted benzothiazole derivatives |
| RS50574B (sr) | 2004-05-24 | 2010-05-07 | F. Hoffmann-La Roche Ag. | (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid 4-hidroksi-4-metil-piperidin-1-karboksilne kiseline |
| WO2005117910A2 (en) | 2004-05-26 | 2005-12-15 | Inotek Pharmaceuticals Corporation | Purine derivatives as adenosine a1 receptor agonists and methods of use thereof |
| US7825102B2 (en) | 2004-07-28 | 2010-11-02 | Can-Fite Biopharma Ltd. | Treatment of dry eye conditions |
| MX2007003271A (es) | 2004-09-20 | 2007-06-05 | Inotek Pharmaceuticals Corp | Derivados de purina y metodos de uso de los mismos. |
| EP1799221A1 (en) * | 2004-10-15 | 2007-06-27 | Cv Therapeutics, Inc. | Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists |
| ES2309814T3 (es) | 2004-11-05 | 2008-12-16 | F. Hoffmann-La Roche Ag | Proceso para la obtencion de derivados del acido isonicotinico. |
| WO2006048884A1 (en) * | 2004-11-08 | 2006-05-11 | Can-Fite Biopharma Ltd. | Therapeutic treatment of accelerated bone resorption |
| AU2005336924A1 (en) * | 2004-11-22 | 2007-04-12 | King Pharmaceuticals Research & Development, Inc. | Enhancing treatment of cancer and HIF-1 mediated disoders with adenosine A3 receptor antagonists |
| WO2006099972A1 (en) | 2005-03-23 | 2006-09-28 | F. Hoffmann-La Roche Ag | Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists |
| JP5048675B2 (ja) | 2005-09-27 | 2012-10-17 | エフ．ホフマン−ラ ロシュ アーゲー | ｍＧｌｕＲ２アンタゴニストとしてのオキサジアゾリルピラゾロ−ピリミジン類 |
| EA015683B1 (ru) | 2005-11-30 | 2011-10-31 | Инотек Фармасьютикалз Корпорейшн | Производные пурина и способы их применения |
| BRPI0621052A2 (pt) * | 2006-01-27 | 2012-07-17 | Can Fite Biopharma Ltd | uso de um agonista de receptor de adenosina a3 (a3ar) |
| WO2008023362A2 (en) * | 2006-08-21 | 2008-02-28 | Can-Fite Biopharma Ltd. | Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer |
| JP2010505848A (ja) * | 2006-10-06 | 2010-02-25 | ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア | 眼内圧を低下させるための種交差性ａ３アデノシン受容体アンタゴニストの効果的送達 |
| GB0625100D0 (en) * | 2006-12-15 | 2007-01-24 | Univ Murcia | Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection |
| US20090088403A1 (en) * | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
| TW200914048A (en) * | 2007-07-17 | 2009-04-01 | Combinatorx Inc | Combinations for the treatment of B-cell proliferative disorders |
| AU2008276451A1 (en) * | 2007-07-17 | 2009-01-22 | Zalicus Inc. | Treatments of B-cell proliferative disorders |
| US20100009934A1 (en) * | 2008-06-09 | 2010-01-14 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
| EP2334179A4 (en) * | 2008-09-08 | 2012-09-26 | Merck Sharp & Dohme | AHCY-HYDROLASE INHIBITOR FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA |
| KR20120022919A (ko) | 2009-05-17 | 2012-03-12 | 캔-파이트 바이오파마 리미티드 | 안압의 감소를 위한 ａ3 아데노신 수용체 작동제 |
| WO2011010306A1 (en) | 2009-07-21 | 2011-01-27 | Ramot At Tel-Aviv University Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
| WO2011074903A2 (ko) * | 2009-12-17 | 2011-06-23 | 이화여자대학교 산학협력단 | Ａ3 아데노신 수용체 효능제를 포함하는 약제학적 조성물 |
| SG182285A1 (en) | 2010-01-11 | 2012-08-30 | Inotek Pharmaceuticals Corp | Combination, kit and method of reducing intraocular pressure |
| US20130045943A1 (en) | 2010-03-03 | 2013-02-21 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | A3ar agonists for the treatment of uveitis |
| EA201290958A1 (ru) | 2010-03-26 | 2013-04-30 | Инотек Фармасьютикалз Корпорейшн | Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств |
| WO2011123518A1 (en) | 2010-03-31 | 2011-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
| SG10201913554YA (en) | 2011-12-22 | 2020-03-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| JP2015504088A (ja) * | 2012-01-23 | 2015-02-05 | キャン−ファイト バイオファーマ リミテッドＣａｎ−Ｆｉｔｅ ＢｉｏＰｈａｒｍａ Ｌｔｄ． | 肝疾患の治療 |
| BR112014018413A8 (pt) | 2012-01-26 | 2017-07-11 | Inotek Pharmaceuticals Corp | Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US8822460B2 (en) | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
| CN105358551A (zh) | 2012-07-19 | 2016-02-24 | 詹森药业有限公司 | Ccr2的八氢环戊并吡咯基拮抗剂 |
| KR101971762B1 (ko) | 2012-08-09 | 2019-08-13 | 캔-파이트 바이오파마 리미티드 | 성기능장애의 치료에 사용하기 위한 a3 아데노신 수용체 리간드 |
| CA2903114A1 (en) | 2013-03-15 | 2014-09-25 | Inotek Pharmaceuticals Corporation | Ophthalmic formulations |
| IL242723B (en) | 2015-11-23 | 2019-12-31 | Can Fite Biopharma Ltd | A3 adenosine receptor ligand for the treatment of ectopic fat accumulation |
| EP3445368B1 (en) | 2016-04-21 | 2024-07-17 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating neurological and cardiovascular conditions |
| IL254535A0 (en) * | 2017-09-17 | 2017-11-30 | Can Fite Biopharma Ltd | Adenosine a3 receptor ligand for use in the management of cytokine release syndrome |
| CN112218638A (zh) | 2018-02-09 | 2021-01-12 | 阿斯特罗赛特制药公司 | 用于治疗成瘾和相关病症的化合物和方法 |
| EP3856741A4 (en) | 2018-09-26 | 2022-06-22 | Astrocyte Pharmaceuticals, Inc. | POLYMORPHOUS COMPOUNDS AND USES THEREOF |
| IL264112A (en) | 2019-01-06 | 2020-07-30 | Fishman Pnina | An a3 adenosine receptor ligand for use for reducing level of adipocytes |
| IT202300014340A1 (it) | 2023-07-10 | 2025-01-10 | Consiglio Nazionale Ricerche | Trattamento di malattie associate alla disfunzione del gene ocrl. |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443836A (en) * | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
| WO1995002604A1 (en) * | 1993-07-13 | 1995-01-26 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
| US5688774A (en) | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| GB2289218A (en) * | 1994-05-06 | 1995-11-15 | Merck & Co Inc | Inhibition of TNFalpha production with agonists of the A2b subtype of the adenosine receptor |
| RU2071770C1 (ru) * | 1994-12-14 | 1997-01-20 | Владислав Алексеевич Шматко | Способ лечения рака шейки матки и яичников |
| RU2071771C1 (ru) * | 1995-01-11 | 1997-01-20 | Владислав Алексеевич Шматко | Способ лечения рака молочной железы |
| US6211165B1 (en) * | 1997-05-09 | 2001-04-03 | The Trustees Of The University Of Pennsylvania | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| IL121272A (en) | 1997-07-10 | 2000-06-01 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia |
| US6048865A (en) * | 1997-07-29 | 2000-04-11 | Medco Research, Inc. | N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator |
| JP2003517423A (ja) * | 1997-07-29 | 2003-05-27 | メドコ リサーチ、インコーポレイテッド | アデノシンレセプターモジュレーターとしてのｎ６−置換アデノシン−５′−ウロナミド |
| AU1363699A (en) * | 1997-10-23 | 1999-05-10 | National Institute Of Health | Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents |
| CA2316994A1 (en) * | 1998-06-08 | 1999-12-16 | Epigenesis Pharmaceuticals, Inc. | Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs |
| US6448253B1 (en) * | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| IL127947A0 (en) | 1999-01-07 | 1999-11-30 | Can Fite Technologies Ltd | Pharmaceutical use of adenosine agonists |
| UA72912C2 (uk) * | 1999-02-01 | 2005-05-16 | Юніверсіті Оф Вірджінія Патент Фаундейшн | Композиція для лікування запальної реакції |
| IL131096A (en) | 1999-07-26 | 2004-09-27 | Can Fite Technologies Ltd | Method for preparing a composition derived from muscle tissue |
-
1999
- 1999-12-23 IL IL13368099A patent/IL133680A0/xx not_active IP Right Cessation
-
2000
- 2000-09-08 DK DK00956773T patent/DK1261322T3/da active
- 2000-09-08 HU HU0203870A patent/HU226913B1/hu unknown
- 2000-09-08 RU RU2002109228/15A patent/RU2239455C2/ru active
- 2000-09-08 CN CNB008148007A patent/CN100358512C/zh not_active Expired - Lifetime
- 2000-09-08 EP EP00956773A patent/EP1261322B1/en not_active Expired - Lifetime
- 2000-09-08 US US09/700,751 patent/US7064112B1/en not_active Expired - Lifetime
- 2000-09-08 ES ES00956773T patent/ES2296637T3/es not_active Expired - Lifetime
- 2000-09-08 AU AU68634/00A patent/AU782826B2/en not_active Expired
- 2000-09-08 KR KR1020027003164A patent/KR100584797B1/ko not_active Expired - Lifetime
- 2000-09-08 BR BR0013905-0A patent/BR0013905A/pt not_active Application Discontinuation
- 2000-09-08 KR KR1020067006473A patent/KR100674529B1/ko not_active Expired - Lifetime
- 2000-09-08 WO PCT/IL2000/000550 patent/WO2001019360A2/en not_active Ceased
- 2000-09-08 MX MXPA02002546A patent/MXPA02002546A/es active IP Right Grant
- 2000-09-08 DE DE60037277T patent/DE60037277T2/de not_active Expired - Lifetime
- 2000-09-08 CA CA002384111A patent/CA2384111C/en not_active Expired - Lifetime
- 2000-09-08 PL PL356469A patent/PL199852B1/pl unknown
- 2000-09-08 HK HK03105018.4A patent/HK1052653B/zh not_active IP Right Cessation
- 2000-09-08 JP JP2001522994A patent/JP4980530B2/ja not_active Expired - Lifetime
- 2000-09-08 PT PT00956773T patent/PT1261322E/pt unknown
-
2005
- 2005-11-25 US US11/286,376 patent/US20060084626A1/en not_active Abandoned
-
2007
- 2007-05-14 JP JP2007128137A patent/JP2007204496A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003514771A5 (https=) | ||
| RU2002109228A (ru) | Фармацевтические композиции, содержащие агонист или антагонист аденозинового рецептора | |
| EP1491201B1 (en) | Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides | |
| US7166581B1 (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
| JP2006524711A5 (https=) | ||
| JP2004531523A5 (https=) | ||
| EP0594667B1 (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
| JP2004517864A (ja) | ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用 | |
| EP3025718A1 (en) | Compositions and methods for combination antiviral therapy | |
| EA010184B1 (ru) | Применение противоопухолевых комбинаций рапамицина с гемцитабином или 5-фторурацилом | |
| EP1959939B1 (en) | Use of a3 adenosine receptor agonist in osteoarthritis treatment | |
| JP6990934B2 (ja) | 異所性脂肪蓄積治療用ａ３アデノシン受容体リガンド | |
| JP2003520783A5 (https=) | ||
| Lech-Maranda et al. | Pharmacological and clinical studies on purine nucleoside analogs-new anticancer agents | |
| US8349792B2 (en) | Combination comprising CNDAC (2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agent | |
| Korycka et al. | Novel purine nucleoside analogues for hematological malignancies | |
| JP2002534390A (ja) | 癌治療におけるアデノシンアゴニスト類の使用 | |
| EP1945265B1 (en) | Antiproliferative combination comprising cyc-682 and a cytotoxic agent | |
| US7776838B1 (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
| KR20030040416A (ko) | 간세포에 약물을 전달하는 방법 및 플라비비리대 감염을치료하는 방법 | |
| US8586561B2 (en) | Anti-tumor agent comprising cytidine derivative and carboplatin | |
| TW202140018A (zh) | 含有尿嘧啶衍生物化合物之抗腫瘤效果增強劑 | |
| Korycka et al. | Novel Purine Nucleoside Analogues for Hematological Malignancies | |
| HK1261991B (en) | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation | |
| HK1224587A1 (en) | Compositions and methods for combination antiviral therapy |